CY1107687T1 - Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας - Google Patents

Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας

Info

Publication number
CY1107687T1
CY1107687T1 CY20071100851T CY071100851T CY1107687T1 CY 1107687 T1 CY1107687 T1 CY 1107687T1 CY 20071100851 T CY20071100851 T CY 20071100851T CY 071100851 T CY071100851 T CY 071100851T CY 1107687 T1 CY1107687 T1 CY 1107687T1
Authority
CY
Cyprus
Prior art keywords
sarp
scleroderma
prevention
therapeutic treatment
treatment
Prior art date
Application number
CY20071100851T
Other languages
English (en)
Inventor
Christine Plater-Zyberk
Christine Power
Jacques Colinge
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1107687T1 publication Critical patent/CY1107687T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στη χρήση της SARP-1 (εκκρινόμενη σχετική με την απόπτωση πρωτεΐνη 1) για την παρασκευή ενός φαρμάκου για τη θεραπευτική αντιμετώπιση και/ή πρόληψη της σκληροδερμίας, ιδίως της συστηματικής σκλήρυνσης.
CY20071100851T 2000-12-06 2007-06-28 Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας CY1107687T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
EP01995681A EP1411970B1 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (1)

Publication Number Publication Date
CY1107687T1 true CY1107687T1 (el) 2012-05-23

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100851T CY1107687T1 (el) 2000-12-06 2007-06-28 Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας

Country Status (30)

Country Link
US (2) US7341995B2 (el)
EP (2) EP1806144A3 (el)
JP (1) JP2004525869A (el)
KR (1) KR100804885B1 (el)
CN (1) CN1323716C (el)
AT (1) ATE359808T1 (el)
AU (2) AU2636602A (el)
BG (1) BG107941A (el)
BR (1) BR0115983A (el)
CA (1) CA2428092A1 (el)
CY (1) CY1107687T1 (el)
CZ (1) CZ20031855A3 (el)
DE (1) DE60128009T2 (el)
DK (1) DK1411970T3 (el)
EA (1) EA005973B1 (el)
EE (1) EE200300213A (el)
ES (1) ES2281463T3 (el)
HK (1) HK1068106A1 (el)
HR (1) HRP20030426A2 (el)
HU (1) HUP0302738A3 (el)
IL (1) IL156069A0 (el)
MX (1) MXPA03005027A (el)
NO (1) NO20032597D0 (el)
NZ (1) NZ525774A (el)
PL (1) PL365316A1 (el)
PT (1) PT1411970E (el)
SK (1) SK8472003A3 (el)
UA (1) UA83790C2 (el)
WO (1) WO2002046225A2 (el)
YU (1) YU45103A (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7638480B2 (en) 2002-04-10 2009-12-29 Laboratoires Serono Sa Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US7893018B2 (en) 2005-11-08 2011-02-22 Foundation For Biomedical Research And Innovation Method of treatment for ischemic heart disease
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
US20140148473A1 (en) * 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6433155B1 (en) * 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
SK287491B6 (sk) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Fúzne proteíny interferónu- beta-1a a ich použitie

Also Published As

Publication number Publication date
CN1553806A (zh) 2004-12-08
MXPA03005027A (es) 2003-09-05
IL156069A0 (en) 2003-12-23
ES2281463T3 (es) 2007-10-01
EE200300213A (et) 2003-08-15
EA200300639A1 (ru) 2003-12-25
SK8472003A3 (en) 2003-10-07
BG107941A (bg) 2004-01-30
CN1323716C (zh) 2007-07-04
DE60128009T2 (de) 2007-08-23
HK1068106A1 (en) 2005-04-22
EP1806144A3 (en) 2008-04-23
US7655628B2 (en) 2010-02-02
KR100804885B1 (ko) 2008-02-20
EP1806144A2 (en) 2007-07-11
KR20030076585A (ko) 2003-09-26
AU2002226366B2 (en) 2007-03-22
HUP0302738A3 (en) 2010-01-28
EP1411970A2 (en) 2004-04-28
US7341995B2 (en) 2008-03-11
YU45103A (sh) 2006-08-17
PT1411970E (pt) 2007-05-31
EP1411970B1 (en) 2007-04-18
JP2004525869A (ja) 2004-08-26
ATE359808T1 (de) 2007-05-15
US20080107627A1 (en) 2008-05-08
CA2428092A1 (en) 2002-06-13
HUP0302738A2 (hu) 2003-11-28
US20050113291A1 (en) 2005-05-26
EA005973B1 (ru) 2005-08-25
DE60128009D1 (de) 2007-05-31
WO2002046225A3 (en) 2004-01-08
NO20032597L (no) 2003-06-06
CZ20031855A3 (cs) 2003-09-17
NZ525774A (en) 2006-03-31
WO2002046225A2 (en) 2002-06-13
PL365316A1 (en) 2004-12-27
NO20032597D0 (no) 2003-06-06
DK1411970T3 (da) 2007-06-04
HRP20030426A2 (en) 2005-04-30
BR0115983A (pt) 2003-12-30
AU2636602A (en) 2002-06-18
UA83790C2 (ru) 2008-08-26

Similar Documents

Publication Publication Date Title
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0314354A (pt) Formação para gentes lipofìlicos
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
CY1107242T1 (el) Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης
DE69432984D1 (de) Therapeutische substituierte guanidine
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE69905170T2 (de) Thiazolopyrimidinderivate
ES2192839T3 (es) Timosina beta 4 oxidada.
ATE445389T1 (de) Liposomale glucocorticoide
RS51737B (sr) Korišćenje inhibitora il-18
SE0002202D0 (sv) New peptides
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
SE9700934D0 (sv) New formulation
NO20073914L (no) Biologisk aktive peptider
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
ATE374203T1 (de) Therapeutische verbindungen und verfahren